ATE456558T1 - Gabanerge modulatoren - Google Patents

Gabanerge modulatoren

Info

Publication number
ATE456558T1
ATE456558T1 AT04763813T AT04763813T ATE456558T1 AT E456558 T1 ATE456558 T1 AT E456558T1 AT 04763813 T AT04763813 T AT 04763813T AT 04763813 T AT04763813 T AT 04763813T AT E456558 T1 ATE456558 T1 AT E456558T1
Authority
AT
Austria
Prior art keywords
gabanergic
modulators
gabanergic modulators
Prior art date
Application number
AT04763813T
Other languages
English (en)
Inventor
Xiao-Fa Lin
David Loughhead
Sanja Novakovic
Counde O'yang
David Putman
Michael Soth
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE456558T1 publication Critical patent/ATE456558T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04763813T 2003-08-14 2004-08-05 Gabanerge modulatoren ATE456558T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49517903P 2003-08-14 2003-08-14
US57438404P 2004-05-25 2004-05-25
PCT/EP2004/008767 WO2005016892A1 (en) 2003-08-14 2004-08-05 Gabanergic modulators

Publications (1)

Publication Number Publication Date
ATE456558T1 true ATE456558T1 (de) 2010-02-15

Family

ID=34198028

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04763813T ATE456558T1 (de) 2003-08-14 2004-08-05 Gabanerge modulatoren

Country Status (14)

Country Link
US (1) US7365211B2 (de)
EP (1) EP1656353B1 (de)
JP (1) JP2007502257A (de)
KR (1) KR100742014B1 (de)
AR (1) AR045255A1 (de)
AT (1) ATE456558T1 (de)
AU (1) AU2004265101B2 (de)
BR (1) BRPI0413540A (de)
CA (1) CA2535406A1 (de)
DE (1) DE602004025354D1 (de)
MX (1) MXPA06001660A (de)
RU (1) RU2376292C2 (de)
TW (1) TW200524878A (de)
WO (1) WO2005016892A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1773781A2 (de) * 2004-08-03 2007-04-18 Wyeth Zur behandlung von kardiovaskulärer erkrankungen nützliche indazole
CA2644910C (en) 2006-03-31 2014-01-28 Abbott Laboratories Indazole compounds
WO2007115966A1 (en) * 2006-04-11 2007-10-18 F. Hoffmann-La Roche Ag Heterocyclic gaba alpha subtype selective receptor modulators
AU2007338102A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Processes for the preparation of (3R, 4R) -N- (4 -chlorophenyl) -1- (2, 2-difluoroethyl) -N' - [2-fluoro-4- (2-oxo-1 (2H) -pyridinyl) phenyl] -3, 4-pyrrolidinedicarboxamide
ES2597083T3 (es) * 2007-05-15 2017-01-13 Merial, Inc. Compuestos de ariloazol-2-il cianoetilamino, procedimiento de fabricación y procedimiento de utilización de los mismos
MY153715A (en) 2008-11-14 2015-03-13 Merial Ltd Enantiomerically enriched aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
EA019685B1 (ru) 2009-02-06 2014-05-30 Янссен Фармасьютикалз, Инк. Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
BRPI1011190A8 (pt) 2009-05-07 2016-11-16 Janssen Pharmaceuticals Inc Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase
ES2519565T3 (es) 2009-07-15 2014-11-07 Janssen Pharmaceuticals Inc. Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa
EP2523949B1 (de) 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Neuartige substituierte Triazolderivate als Gamma-Sekretase-Modulatoren
EP2582666B1 (de) * 2010-06-16 2014-08-13 Purdue Pharma L.P. Arylsubstituierte indole und ihre verwendung als kalzium-kanal-blocker
CA2827969A1 (en) 2011-03-24 2012-09-27 Janssen Pharmaceuticals, Inc. Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
NZ702611A (en) 2012-05-16 2016-10-28 Cellzome Ltd Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease
JP2014034523A (ja) * 2012-08-07 2014-02-24 Manac Inc モノまたはジハロゲノピリジルアミン類の製造方法
US8822689B2 (en) 2012-09-19 2014-09-02 Merial Limited Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
JP6249952B2 (ja) * 2012-10-16 2017-12-20 武田薬品工業株式会社 複素環化合物
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
ES2612215T3 (es) 2013-01-17 2017-05-12 Janssen Pharmaceutica, N.V. Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
WO2019200061A1 (en) * 2018-04-11 2019-10-17 The General Hospital Corporation Anesthetic compounds
EP3810610A1 (de) 2018-05-18 2021-04-28 Incyte Corporation Kondensierte pyrimidinderivate als a2a/a2b-inhibitoren
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
WO2020065642A1 (en) 2018-09-25 2020-04-02 Pepticom Ltd. Positive allosteric modulators of gabaa receptor
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2022006541A1 (en) * 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
CN116462628A (zh) * 2022-01-12 2023-07-21 联化科技新材(台州)有限公司 一种2-溴-5-氨基吡啶的制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040027A1 (en) * 1996-04-19 1997-10-30 Akzo Nobel N.V. Substituted benzylamines and their use for the treatment of depression
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
GB0008696D0 (en) * 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic agents
AU2001267963A1 (en) * 2000-06-30 2002-01-08 Light Eye Developments Limited Improved dynamo
AU2001277621A1 (en) 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
JP2004508359A (ja) * 2000-09-06 2004-03-18 ニューロゲン コーポレイション アリール置換テトラヒドロインダゾール、及び、gaba−a受容体に対するリガンドとしてのそれらの使用
BR0316950A (pt) * 2002-12-02 2006-01-17 Hoffmann La Roche Derivados de indazol como antagonistas de crf

Also Published As

Publication number Publication date
KR20060037440A (ko) 2006-05-03
RU2006107438A (ru) 2007-09-20
WO2005016892A1 (en) 2005-02-24
MXPA06001660A (es) 2006-04-28
RU2376292C2 (ru) 2009-12-20
JP2007502257A (ja) 2007-02-08
EP1656353A1 (de) 2006-05-17
DE602004025354D1 (de) 2010-03-18
KR100742014B1 (ko) 2007-07-23
EP1656353B1 (de) 2010-01-27
TW200524878A (en) 2005-08-01
BRPI0413540A (pt) 2006-10-10
US7365211B2 (en) 2008-04-29
CA2535406A1 (en) 2005-02-24
AU2004265101A1 (en) 2005-02-24
AR045255A1 (es) 2005-10-19
AU2004265101B2 (en) 2009-06-11
US20050101614A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
ATE456558T1 (de) Gabanerge modulatoren
DE602004026540D1 (de) Kurbelwellenmomentmodulator
FI20020800A7 (fi) Modulaattori
DE50311137D1 (de) Eriebauteile
DE602004020364D1 (de) Benzoimidazolverbindungen
DE602004029114D1 (de) Trennanalysator
DE502004010381D1 (de) Um
EP1603979A4 (de) Antifoulinglack
AT502792A5 (de) Düsenanpressvorrichtung
DE602004001602D1 (de) Motorluftansaugkrümmer
DE60319796D1 (de) tsdetektion
DE502004007911D1 (de) Wischblatt
DE60307903D1 (de) Impedanzanpassungskoppler
DK2447252T3 (da) Theramuteinmodulatorer
DE60331697D1 (de) Verzögerungszeitdiskriminator
DE602004018247D1 (de) Modulator
DE602004002038D1 (de) Buschschneider
DK1581307T3 (da) Irs modulatorer
FIU20030402U0 (fi) Spraypäällystysyksikkö
DE602004010064D1 (de) Freilaufkupplungsfeder
DE502004010244D1 (de) En
DE502004008889D1 (de) Schaltgabel
DE502004005162D1 (de) Leistungsregelvorricthung
DE602004003805D1 (de) Gasfeder
EP1639260A4 (de) Hochdruckdosierventil

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties